Clinical Trials
34 trialsNCT07431281 2026-05-27
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
AstraZeneca
Phase 3 Recruiting
NCT06768164 2026-05-20
BYQoL-GC
Assistance Publique - Hôpitaux de Paris
Phase 3 Recruiting
NCT07488611 2026-05-19
PROGAIN
Soonchunhyang University Hospital
Phase 3 Recruiting
NCT06346197 2026-04-21
CIME
Centre Leon Berard
Phase 3 Recruiting
NCT07217704 2026-04-20
FAPI-GO
SOFIE
Phase 3 Recruiting
NCT06731478 2026-03-16
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Daiichi Sankyo
Phase 3 Recruiting
NCT05871099 2026-03-06
Laparoscopic Gastrectomy With D2 Lymphadenectomy Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) or Not
The Affiliated Hospital of Qingdao University
Phase 3 Recruiting
NCT06532006 2026-02-27
A Phase â…¢ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
Shanghai Henlius Biotech
Phase 3 Recruiting
NCT04871412 2026-01-30
POISE
Ottawa Hospital Research Institute
Phase 3 Recruiting
NCT07366528 2026-01-26
Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer
Ruijin Hospital
Phase 3 Recruiting
NCT07315750 2026-01-21
A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
RemeGen Co., Ltd.
Phase 3 Recruiting
NCT04342910 2026-01-20
Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Recruiting
NCT07304271 2025-12-26
IPa-Gastric
Karolinska University Hospital
Phase 3 Recruiting
NCT06793917 2025-07-20
Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
Fujian Cancer Hospital
Phase 3 Recruiting
NCT06949033 2025-07-10
Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Lanzhou University Second Hospital
Phase 3 Recruiting
NCT06925243 2025-04-22
Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Lanzhou University Second Hospital
Phase 3 Recruiting
NCT05593458 2025-04-09
TACTIC
Zhejiang University
Phase 3 Recruiting
NCT06755554 2025-03-30
ICGastr
Ukrainian Society of Clinical Oncology
Phase 3 Recruiting
NCT04214990 2024-12-27
EASTERN
National Cancer Center, Korea
Phase 3 Recruiting
NCT06296706 2024-11-14
A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 3 Recruiting
NCT04447352 2024-11-12
PREVENT
Krankenhaus Nordwest
Phase 3 Recruiting
NCT06608381 2024-09-23
Comparison Partial Versus Total Omentectomy in Minimal Invasive Distal Gastrectomy for cT3/4a Gastric Cancer (KLASS-10)
Gangnam Severance Hospital
Phase 3 Recruiting
NCT06313567 2024-07-08
Metronomic Capecitabine in Stage III Gastric Cancer
Fudan University
Phase 3 Recruiting
NCT06161207 2024-06-24
3D-4K-ICG
Fujian Medical University
Phase 3 Recruiting
NCT04597294 2024-03-06
CHIMERA
Jagiellonian University
Phase 3 Recruiting
NCT01917552 2024-02-28
Adjuvant Capecitabine Versus Observation Alone in Curatively Resected Stage IB Gastric Cancer((KCSG ST14-05): CATALYSIS
Asan Medical Center
Phase 3 Recruiting
NCT01935778 2024-02-28
Compare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxliplatin Versus Capecitabine/Oxaliplatin in Advanced Gastric Cancer at Stage IIIb and IV(KCSG ST15-08): TRIUMPH
Asan Medical Center
Phase 3 Recruiting
NCT06177041 2024-02-28
M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.
FutureGen Biopharmaceutical (Beijing) Co., Ltd
Phase 3 Recruiting
NCT05918094 2024-01-26
Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
Sun Yat-sen University
Phase 3 Recruiting
NCT05264896 2023-09-07
Perioperative FLOT vs Adjuvant XELOX for CA Stomach
Chinese University of Hong Kong
Phase 3 Recruiting
NCT04787354 2022-02-21
Optimal Duration of Oxaliplatin in Adjuvant XELOX for Gastric Cancer Patients (EXODOX)
Hallym University Medical Center
Phase 3 Recruiting
NCT04997837 2021-08-10
Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma
Fudan University
Phase 3 Recruiting
NCT04483076 2021-01-20
RESONANCE-II
Chinese PLA General Hospital
Phase 3 Recruiting
NCT03941561 2019-05-31
S-1 for 9 Months Versus 1 Year for Stage II Gastric Cancer (SMAC）
Fudan University
Phase 3 Recruiting